LGND - Ligand Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
95.71
-1.37 (-1.41%)
At close: 4:00PM EDT

95.71 0.00 (0.00%)
After hours: 4:36PM EDT

Stock chart is not supported by your current browser
Previous Close97.08
Open96.26
Bid95.64 x 900
Ask95.72 x 1000
Day's Range95.64 - 97.55
52 Week Range88.23 - 278.62
Volume195,005
Avg. Volume378,314
Market Cap1.82B
Beta (3Y Monthly)1.58
PE Ratio (TTM)3.13
EPS (TTM)30.55
Earnings DateNov 6, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-07-02
1y Target Est191.80
Trade prices are not sourced from all markets
  • 3 Top Biotech Stocks to Buy in August
    Motley Fool

    3 Top Biotech Stocks to Buy in August

    In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.

  • Business Wire

    Ligand Partner CASI Pharmaceuticals Launches EVOMELA® in China

    Ligand Pharmaceuticals Incorporated (LGND) partner CASI Pharmaceuticals, Inc. (CASI), a U.S. biopharmaceutical company focused on developing and accelerating the launch of innovative therapeutics and pharmaceutical products in China, the U.S., and throughout the world, announces the official product launch of melphalan hydrochloride for injection (EVOMELA) in China which is the first commercial product launch for CASI. Melphalan hydrochloride for injection (EVOMELA) received market approval by the China National Medical Products Administration (NMPA) for use as high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplant in patients with multiple myeloma, and as a palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.

  • Thomson Reuters StreetEvents

    Edited Transcript of LGND earnings conference call or presentation 30-Jul-19 1:00pm GMT

    Q2 2019 Ligand Pharmaceuticals Inc Earnings Call

  • GuruFocus.com

    Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $176,582 of Shares

    CEO of Ligand Pharmaceuticals Inc (30-Year Financial, Insider Trades) John L Higgins (insider trades) bought 1,850 shares of LGND on 07/31/2019 at an average price of $95.45 a share. Continue reading...

  • Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
    Zacks

    Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

    Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

  • Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript
    Motley Fool

    Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript

    LGND earnings call for the period ending June 30, 2019.

  • Benzinga

    Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings

    Ligand Pharmaceuticals Inc. (NASDAQ: LGND) shares are down 10.5% on Tuesday following the company’s earnings report, but one of the company’s most vocal critics and short sellers is leaning into its bearish trade. On Tuesday, Ligand short seller Lemelson Capital Management said the firm has been adding to its short position against Ligand and is calling for an investigation into alleged crimes committed by the company. “Sadly, investors have been ruined by Ligand’s alleged scheme while the SEC has ignored the red flags and botched opportunities for a proper investigation of the company,” Lemelson Capital’s Chief Investment Officer Fr.

  • Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates
    Zacks

    Ligand Pharmaceuticals (LGND) Surpasses Q2 Earnings and Revenue Estimates

    Ligand (LGND) delivered earnings and revenue surprises of 11.48% and 9.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Ligand Reports Second Quarter 2019 Financial Results

    Conference Call Begins at 9:00 a.m. Eastern Time Today

  • Business Wire

    Ligand Acquires Ab Initio Biotherapeutics, an Antigen-Discovery Company

    Ligand Pharmaceuticals Incorporated (LGND) announces the signing of an agreement with Ab Initio Biotherapeutics whereby Ligand will acquire Ab Initio for $12 million in cash. Ab Initio was a privately held antigen-discovery company based in South San Francisco, California. Antigen design and preparation are the first steps necessary for the discovery of therapeutic antibodies.

  • Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • PR Newswire

    Lemelson Capital Management Announces 1H, 2019 Financial Results for The Amvona Fund, LP

    Short position in Ligand pharmaceuticals, long position in Geospace Technologies, contribute to 70.27 percent net return in 1H, 2019 SHELBURNE, Vt ., July 16, 2019 /PRNewswire/ -- Lemelson Capital Management, ...

  • Business Wire

    Ligand to Report Second Quarter 2019 Results on July 30th

    Ligand Pharmaceuticals Incorporated announced today plans to report second quarter 2019 financial results on July 30, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr, and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value
    Simply Wall St.

    Is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Expensive For A Reason? A Look At Its Intrinsic Value

    How far off is Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) from its intrinsic value? Using the most recent...

  • Business Wire

    Ligand Announces Positive Top Line Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Ligand Pharmaceuticals Incorporated (LGND) today announced positive top line results from a Phase 1 clinical trial of its internal Captisol-enabled (CE) Iohexol program. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. Based on top line data, the trial achieved the primary endpoint demonstrating pharmacokinetic bioequivalence between CE-Iohexol injection and a reference Iohexol injection (OMNIPAQUE™) after intravenous (IV) administration in healthy adults.

  • Markit

    See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.

    Ligand Pharmaceuticals Inc NASDAQ NMS:LGNDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding LGND totaled $64.13 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation
    PR Newswire

    Ligand and SQ Innovation Enter into Exclusive Worldwide Captisol® License and Supply Agreements for High-Concentration Furosemide Formulation

    SQ Innovation will use Ligand's Captisol technology to achieve a smaller delivery volume for more cost-effective diuretic treatment in heart failure. The smaller delivery volume enables use of established drug container and device technology developed for insulin and other biologics, resulting in faster development and reduced cost. SQ Innovation to use advanced 3 mL drug delivery platform by Sensile Medical AG, a Gerresheimer company, for the novel treatment.

  • Business Wire

    ZULRESSO™ (brexanolone) CIV, a Product for Treating Postpartum Depression Using Ligand’s Captisol® in its Formulation, Launched by Sage Therapeutics

    Ligand Pharmaceuticals Incorporated (LGND) today announced that Sage Therapeutics has launched ZULRESSO™ (brexanolone) injection, which was approved by the U.S. Food and Drug Administration (FDA) on March 19, 2019, and is the first and only treatment specifically approved for postpartum depression (PPD), one of the most common medical complications during and after pregnancy. With this launch, ZULRESSO is the 11th FDA-approved drug to use Ligand’s patented Captisol technology. ZULRESSO is administered via continuous intravenous (IV) infusion for 2.5 days under the supervision of healthcare providers in sites of care certified under the ZULRESSO Risk Evaluation and Mitigation Strategy (REMS) program.

  • What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future?
    Simply Wall St.

    What does Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Balance Sheet Tell Us About Its Future?

    Small and large cap stocks are widely popular for a variety of reasons, however, mid-cap companies such as Ligand...

  • Ligand Inks Oncology Drug Discovery Deal With PhoreMost
    Zacks

    Ligand Inks Oncology Drug Discovery Deal With PhoreMost

    Ligand's (LGND) subsidiary Vernalis enters research agreement with privately-held PhoreMost to design compounds targeting an undisclosed novel oncology target.

  • Business Wire

    Ligand Subsidiary Vernalis and PhoreMost Limited Announce Drug Discovery Collaboration for Novel Oncology Target

    Ligand Pharmaceuticals Incorporated (LGND) and PhoreMost Limited today announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target. PhoreMost has identified and validated the target using its next-generation SITESEEKER® phenotypic screening technology. Ligand will now apply its Vernalis Design Platform (VDP) to design small molecule inhibitors against the target, to help rapidly progress compounds through hit-to-lead and lead optimization stages.